BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
Bergen, Norway, 16 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the third quarter of 2021. A presentation and live webcast by BerGenBio’s senior management will take place at 10am CET today, please see below for details. Operational Highlights – third quarter of 2021 (including post-period end) · Martin Olin appointed Chief Executive Officer, bringing 20 years of executive experience in the pharmaceutical and biotechnology industry.